InfraReDx CEO to Discuss Vulnerable Plaque Identification with LipiScan(TM) Coronary Imaging System at Cardiovascular Research Technologies 2010 Forum

BURLINGTON, Mass., Feb. 18 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's founder and chief executive officer, James E. Muller, M.D., will present and participate in a number of sessions and panel discussions during the annual Cardiovascular Research Technologies (CRT) 2010 meeting. CRT 2010, sponsored by Washington, D.C. based Washington Hospital Center, is being held February 21-23 at the city's Omni Shoreham Hotel. Dr. Muller is an invited faculty member for this educational summit attended by interventional cardiologists and vascular medicine specialists. The capabilities of InfraReDx's commercially available LipiScan™ Coronary Imaging System will be highlighted by Dr. Muller at the meeting and at the company's exhibition booth, #210.  

InfraReDx's LipiScan near-infrared (NIR) spectroscopy catheter is the only FDA-cleared product to detect and assess the intracoronary composition of lipid core plaque, which cannot be detected by commonly used diagnostic tests such as treadmill exams and coronary angiograms. In addition to the benefits of NIR, as currently integrated into the LipiScan system, Dr. Muller will also discuss the potential advantages of integrating intravascular ultrasound (IVUS) capabilities.

His presentation schedule during CRT 2010 is as follows:

Monday, February 22 – Emerging Technologies

Dr. Muller will speak during the Emerging Technologies Session presentation titled "Imaging", which is scheduled for February 22 from 8:00 a.m. to 10:00 a.m. ET. As part of this presentation, he will discuss "Lipid Detection InfraReDx Technology Integrated with IVUS," and will also participate in the panel session following formal remarks.

Monday, February 22 – Vulnerable Plaque Summit

Dr. Muller will join numerous world renowned Interventional Cardiologists presenting on the critical topic of vulnerable plaque and will be speaking during the Vulnerable Plaque Summit presentation titled "Invasive Imaging of Vulnerable Plaques II", which runs on February 22 from 3:30 p.m. to 4:40 p.m. ET. As part of this presentation he will present an update on "Near Infrared Spectroscopy Technology," and will also participate in the panel session following formal remarks.

Tuesday, February 23 – Atherosclerosis & Lipid Management

Dr. Muller will speak during the Atherosclerosis & Lipid Management session, as a participant in a debate titled "Identification of the Vulnerable Plaque: Critical Concept or Hype?" which is scheduled to begin at 10:30 a.m. ET.

Dr. Muller is a globally recognized expert on the subject of vulnerable plaques, a key field of study since he and colleagues first introduced the concept in 1989. Dr. Muller's work, and that of InfraReDx, is focused on lipid (fatty) core plaques known to rupture and form dangerous blood clots, leading to heart attacks. These vulnerable plaques are widely considered to be responsible for a significant number of stenting post-procedure complications and are believed to be the primary cause of acute cardiac events and sudden cardiac death, the leading cause of death in the developed world.

About InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, is a privately-funded medical device company founded in 1998 and focused on intravascular characterization of disease in the coronary arteries. InfraReDx is the maker of the LipiScan™ system, a novel near-infrared (NIR) spectroscopy catheter that can detect the lipid core coronary plaques suspected to cause most heart attacks and known to complicate stenting procedures. For more information, visit www.infraredx.com.  

About CRT 2010

Cardiovascular Research Technologies (CRT) 2010, is a multi-modular meeting that focuses on the advances and changes in the field of cardiovascular medicine. With the significant incidence and prevalence of coronary and peripheral artery disease in the United States, it is essential for healthcare professionals to stay abreast of the developments in this field. CRT 2010 attendees will include cardiologists, basic scientists, vascular medicine specialists, cardiothoracic surgeons, nurses, technologists and other health care professionals with a special interest in the field of interventional and vascular medicine. CRT 2010 is being held by Washington, D.C. based Washington Hospital Center, an accredited Continuing Medical Education facility. The meeting will provide access to the world's leading clinicians and the latest research in order to improve practice and treatment outcomes. For more information, please visit www.crtmeeting.org.

SOURCE InfraReDx, Inc.